Three cases suggest some clinicians lack understanding of relatively common autosomal recessive disorders and are misinterpreting test reports.
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results